This is a temporary backup site for TRENDS MENA while our primary website is being restored following a regional disruption affecting Amazon Web Services cloud infrastructure in the GCC.

Search Site

BYD 2025 revenue surges

The EV manufacturer reported net profit of $.3.3bn for 9M 2025.

Aramco net income $28bn

Capital investment during Q3 2025 $12.9bn on investments in energy projects.

e& revenue up 23%

Consolidated net profit reached $2.94 billion during 2025.

Al Rajhi profit up 26%

Operating income for 2025 increased 22% to SAR 39 bn.

Emirates NBD 2025 profit $8.5bn

Total income rises by 12 percent, operating profit up 13%.

Burjeel Holdings profit surges

  • The company posted a162.6 percent increase to $37.30 million during the third quarter of 2023
  • It plans to set up two medical centres in Dubai and Abu Dhabi and one Burjeel Day Surgery Centre in Al Dhafra

Abu Dhabi, UAE–Burjeel Holdings has reported a 76.4 percent increase in net profit to $98.57 million in the first nine months of 2023, enabled by revenue growth, increased operational efficiencies and lower finance costs.

In a statement on Tuesday, Burjeel said that net profit increased by 162.6% to $37.30 million during the third quarter of 2023.

The company delivered robust revenue growth of 17.2% to $898 for the first nine months of 2023, driven by a 10.6% increase in total patient footfall to 4.4 million patients.

Burjeel Holdings continues to deliver on its strategic priorities of driving growth by elevating patient yield and utilisation, capitalising on the Group’s world-class healthcare assets and infrastructure.

Burjeel also continues to expand its network of medical centres, which serve as a key referral source for its speciality hospitals. The Group plans to launch two medical centres in Dubai and Abu Dhabi and one Burjeel Day Surgery Centre in Al Dhafra over the next six months.

John Sunil, Chief Executive Officer of Burjeel Holdings, said, “Burjeel Holdings delivered another strong set of results during the third quarter of 2023, as we focused on executing our strategy to drive patient yields through the provision of highly specialised complex care delivered by world-class medical professionals as we further ramped up our growth assets.

“This enabled us to accelerate our growth trajectory with Group revenue increasing 23.8% and EBITDA growing by an impressive 34.1% in the third quarter of 2023, driven by both an increase in patient footfall and the expansion of our complex care offering.

Cash Flow from Operating Activities increased by 64.0% during the nine months of 2023, driven by EBITDA growth and optimisation of working capital. Additionally, Free Cash Flow (FCF) Conversion1 grew to 45%, up from 35% in the prior year.

The Group’s Net Debt / Pre-IFRS 16 EBITDA decreased from 1.5x as of 31st December 2022 to 1.3x as of 30 September 2023. The strength of the group’s balance sheet provides adequate financial flexibility to pursue growth opportunities going forward.